It’s time to end the bullshit
Thank you Hempman Richard Rose for having sent me this most dramatic clinical demonstration of the strong protective, life saving power that NAC (N-acetyl cycyeine) can have on people infected with a deadly respiratory virus.NAC-1997-Italian-Study
The attached article shows how high doses of NAC can have extremely beneficial effects on a population of people suffering influenza infection. Influenza kills using the same mechanism as does COV-19, excess free radical production induced ARDS (Adult Respiratory Distress Syndrome).
The question we the people of the world must ask ourselves is why discussions of inexpensive nutraceuticals, including NAC, Vit D and cannabinoids (CBD), have been excluded from public discussion? Wake up Dr Fauci, Dr. Adams etc.
As metabolic beings, we all have the most fundamental right to metabolic freedom. Many people choose alternatives to FDA approved pharmaceuticals for improving their health .All science-based options must be discussed publicly.The pharmaceutical perspective cannot be presented as the only option. It’s un-America and illegal.
Please listen Mr. President. The economy can only start humming once sufficient numbers of people have been infected. The metabolic approach will allow people to be infected and recover more rapidly, while not overloading life support when necessary. drbob
Attenuation of influenza-like symptomatology and improvement of cell-mediated immu- nity with long-term N-acetylcysteine treatment. S. De Flora, C. Grassi, L. Carati. ©ERS Journal Ltd 1997.
ABSTRACT: N-acetylcysteine (NAC), an analogue and precursor of reduced glu- tathione, has been in clinical use for more than 30 yrs as a mucolytic drug. It has also been proposed for and/or used in the therapy and/or prevention of several respiratory diseases and of diseases involving an oxidative stress, in general. The objective of the present study was to evaluate the effect of long-term treatment with NAC on influenza and influenza-like episodes.
A total of 262 subjects of both sexes (78% ≥65 yrs, and 62% suffering from non- respiratory chronic degenerative diseases) were enrolled in a randomized, double- blind trial involving 20 Italian Centres. They were randomized to receive either placebo or NAC tablets (600 mg) twice daily for 6 months. Patients suffering from chronic respiratory diseases were not eligible, to avoid possible confounding by an effect of NAC on respiratory symptoms.
NAC treatment was well tolerated and resulted in a significant decrease in the frequency of influenza-like episodes, severity, and length of time confined to bed. Both local and systemic symptoms were sharply and significantly reduced in the NAC group. Frequency of seroconversion towards A/H1N1 Singapore 6/86 influenza virus was similar in the two groups, but only 25% of virus-infected subjects under NAC treatment developed a symptomatic form, versus 79% in the placebo group. Evaluation of cell-mediated immunity showed a progressive, significant shift from anergy to normoergy following NAC treatment.
Administration of N-acetylcysteine during the winter, thus, appears to provide a significant attenuation of influenza and influenza-like episodes, especially in elder- ly high-risk individuals. N-acetylcysteine did not prevent A/H1N1 virus influenza infection but significantly reduced the incidence of clinically apparent disease. Eur Respir J 1997; 10: 1535–1541. Mar 29, 2020